Code | CSB-RA006169A33phHU |
Size | US$210 |
Order now | |
Image |
|
Have Questions? | Leave a Message or Start an on-line Chat |
Application | Recommended Dilution |
---|---|
IF | 1:20-1:200 |
The vectors expressing anti-CTNNB1 antibody were constructed as follows: immunizing an animal with a synthesized peptide derived from human Phospho-CTNNB1 (S33/S37), isolating the positive splenocyte and extracting RNA, obtaining DNA by reverse transcription, sequencing and screening CTNNB1 antibody gene, and amplifying heavy and light chain sequence by PCR and cloning them into plasma vectors. After that, the vector clones were transfected into the mammalian cells for production. The product is the recombinant CTNNB1 antibody. Recombinant CTNNB1 antibody in the culture medium was purified using affinity-chromatography. It can react with CTNNB1 protein from Human and is used in the ELISA, IF.
CTNNB1 (Catenin Beta 1) is a protein-coding gene. Diseases associated with CTNNB1 include Pilomatrixoma and Neurodevelopmental Disorder with Spastic Diplegia and Visual Defects. Associated pathways include the NF-kappaB pathway and apoptotic cleavage of cellular proteins. According to some studies, CTNNB1 may have the following characteristics.
CTNNB1 mutations are highly prevalent in sporadic castrated tumors. Mutations in the β-catenin gene (CTNNB1) have recently been implicated in the pathogenesis of some colon cancers and melanomas. CTNNB1 signaling plays a key role in the development of a considerable proportion of prostate cancer. The nuclear expression of β-catenin is an accurate immunohistochemical surrogate for CTNNB1 exon 3 mutations and thus may be considered in risk stratification for endometrial cancer.
There are currently no reviews for this product.